Skip to main content

Advertisement

SpringerLink
Log in

Time to move forward from “first-generation” prognostic gene signatures in early breast cancer

  • Invited Commentary
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

The Original Article was published on 29 August 2010

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Sotiriou C, Piccart MJ (2007) Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care? Nat Rev Cancer 7(7):545–553. doi:10.1038/nrc2173

    Article  PubMed  CAS  Google Scholar 

  2. Sotiriou C, Pusztai L (2009) Gene-expression signatures in breast cancer. N Engl J Med 360(8):790–800. doi:10.1056/NEJMra0801289

    Article  PubMed  CAS  Google Scholar 

  3. van ‘t Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R, Friend SH (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415(6871):530–536

    Article  PubMed  Google Scholar 

  4. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, Hiller W, Fisher ER, Wickerham DL, Bryant J, Wolmark N (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351(27):2817–2826

    Article  PubMed  CAS  Google Scholar 

  5. Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J, Nordgren H, Farmer P, Praz V, Haibe-Kains B, Desmedt C, Larsimont D, Cardoso F, Peterse H, Nuyten D, Buyse M, Van de Vijver MJ, Bergh J, Piccart M, Delorenzi M (2006) Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 98(4):262–272

    Article  PubMed  CAS  Google Scholar 

  6. Buyse M, Loi S, van ’t Veer L, Viale G, Delorenzi M, Glas AM, d’Assignies MS, Bergh J, Lidereau R, Ellis P, Harris A, Bogaerts J, Therasse P, Floore A, Amakrane M, Piette F, Rutgers E, Sotiriou C, Cardoso F, Piccart MJ (2006) Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst 98(17):1183–1192

    Article  PubMed  CAS  Google Scholar 

  7. Dowsett M, Cuzick J, Wale C, Forbes J, Mallon EA, Salter J, Quinn E, Dunbier A, Baum M, Buzdar A, Howell A, Bugarini R, Baehner FL, Shak S (2010) Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a transATAC study. J Clin Oncol 28(11):1829–1834. doi:10.1200/JCO.2009.24.4798

    Article  PubMed  Google Scholar 

  8. Haibe-Kains B, Desmedt C, Piette F, Buyse M, Cardoso F, Van’t Veer L, Piccart M, Bontempi G, Sotiriou C (2008) Comparison of prognostic gene expression signatures for breast cancer. BMC Genomics 9:394. doi:10.1186/1471-2164-9-394

    Article  PubMed  Google Scholar 

  9. EGAPP (2009) Recommendations from the EGAPP working group: can tumor gene expression profiling improve outcomes in patients with breast cancer? Genet Med 11(1):66–73. doi:10.1097/GIM.0b013e3181928f56

    Google Scholar 

  10. Cardoso F, Van’t Veer L, Rutgers E, Loi S, Mook S, Piccart-Gebhart MJ (2008) Clinical application of the 70-gene profile: the mind act trial. J Clin Oncol 26(5):729–735

    Article  PubMed  Google Scholar 

  11. Sparano JA, Paik S (2008) Development of the 21-gene assay and its application in clinical practice and clinical trials. J Clin Oncol 26(5):721–728

    Article  PubMed  Google Scholar 

  12. Haibe-Kains B, Desmedt C, Rothe F, Piccart M, Sotiriou C, Bontempi G (2010) A fuzzy gene expression-based computational approach improves breast cancer prognostication. Genome Biol 11(2):R18. doi:10.1186/gb-2010-11-2-r18

  13. Kattan MW (2003) Judging new markers by their ability to improve predictive accuracy. J Natl Cancer Inst 95(9):634–635

    Article  PubMed  CAS  Google Scholar 

  14. Dunkler D, Michiels S, Schemper M (2007) Gene expression profiling: does it add predictive accuracy to clinical characteristics in cancer prognosis? Eur J Cancer 43(4):745–751. doi:10.1016/j.ejca.2006.11.018

    Article  PubMed  CAS  Google Scholar 

  15. Haibe-Kains B, Desmedt C, Sotiriou C, Bontempi G (2008) A comparative study of survival models for breast cancer prognostication based on microarray data: does a single gene beat them all? Bioinformatics 24(19):2200–2208. doi:10.1093/bioinformatics/btn374

    Article  PubMed  CAS  Google Scholar 

  16. Wirapati P, Sotiriou C, Kunkel S, Farmer P, Pradervand S, Haibe-Kains B, Desmedt C, Ignatiadis M, Sengstag T, Schutz F, Goldstein DR, Piccart M, Delorenzi M (2008) Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res 10(4):R65. doi:10.1186/bcr2124

    Google Scholar 

  17. Desmedt C, Haibe-Kains B, Wirapati P, Buyse M, Larsimont D, Bontempi G, Delorenzi M, Piccart M, Sotiriou C (2008) Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res 14(16):5158–5165. doi:10.1158/1078-0432.CCR-07-4756

    Article  PubMed  CAS  Google Scholar 

  18. Desmedt C, Piette F, Loi S, Wang Y, Lallemand F, Haibe-Kains B, Viale G, Delorenzi M, Zhang Y, d’Assignies MS, Bergh J, Lidereau R, Ellis P, Harris AL, Klijn JG, Foekens JA, Cardoso F, Piccart MJ, Buyse M, Sotiriou C (2007) Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the transbig multicenter independent validation series. Clin Cancer Res 13(11):3207–3214

    Article  PubMed  CAS  Google Scholar 

  19. Reis-Filho JS, Weigelt B, Fumagalli D, Sotiriou C (2010) Molecular profiling: moving away from tumor philately. Sci Transl Med 2(47):47ps43. doi:10.1126/scitranslmed.3001329

Download references

Conflict of interest

Christos Sotiriou is a named inventor on the patent of the Gene Expression Grade Index (GGI).

Author information

Authors and Affiliations

  1. Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Universite Libre de Bruxelles, 121 Boulevard de Waterloo, 1000, Bruxelles, Belgium

    Christine Desmedt, Stefan Michiels, Sherene Loi & Christos Sotiriou

  2. Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, and Department of Biostatistics, Harvard School of Public Health, Boston, MA, USA

    Benjamin Haibe-Kains

Authors
  1. Christine Desmedt
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stefan Michiels
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Benjamin Haibe-Kains
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sherene Loi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Christos Sotiriou
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christos Sotiriou.

Additional information

This is an invited commentary to article doi:10.1007/s10549-010-1145-z.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Desmedt, C., Michiels, S., Haibe-Kains, B. et al. Time to move forward from “first-generation” prognostic gene signatures in early breast cancer. Breast Cancer Res Treat 128, 643–645 (2011). https://doi.org/10.1007/s10549-010-1213-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-010-1213-4

Keywords

Search

Navigation